Overview
- Peptide CGEQINYGRVEK, corresponding to amino acid residues 73 - 84 of rat 5-HT7 (Accession P32305). Extracellular, N-terminus.
- Rat and mouse brain lysates; mouse BV-2 microglia, human THP-1 monocytic leukemia and MEG-01 megakaryoblastic leukemia cell lysates (1:400-1:2000).
Western blot analysis of rat brain lysate (lanes 1 and 3) and mouse brain lysate (lanes 2 and 4):1, 2. Anti-5HT7 Receptor/HTR7 (extracellular) Antibody (#ASR-037), (1:400).
3, 4. Anti-5HT7 Receptor/HTR7 (extracellular) Antibody, preincubated with 5HT7 Receptor/HTR7 (extracellular) Blocking Peptide (#BLP-SR037).
- Rat and mouse brain sections (1:300).
- Human MEG-01 megakaryoblastic leukemia cells (5 µg).
5-HT7 receptor is a G-protein coupled receptor (GPCR) that is activated by Serotonin. Like all other members, 5-HT7 has seven transmembrane domains. In addition, it contains a hydrophobic domain located at its N-terminal end1.
The signaling cascades activated by these receptors take part in circadian rhythm, learning and memory, hippocampal signaling and smooth muscle relaxation. It was also shown to have a role in several disorders including Autism, neuropsychiatric disorders, Epilepsy and Alzheimer's disease2,4.
5-HT7 is encoded by HTR7 gene and it has three splice variants encoding proteins that differ in the length of their carboxy-terminal ends. The splice variants are differentially expressed in the spleen, kidney, heart, thalamus, hindbrain, hippocampus, cortex, caudate, striatum and cerebellum3.
Due to its involvement in central and the peripheral nervous systems, endocrine system and its involvement in various diseases and syndromes, 5-HT7 receptor represents an interesting target for the treatment and prevention of various pathologies. Selective ligands are being studied in order to regulate this receptor's activity4.
